title: The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress.
abstract: We have developed a model system in which rat basal forebrain cholinergic neurons degenerate progressively when maintained in culture conditions that make them susceptible to low-level oxidative stress. In this study, we showed that cholinergic neurons identified by acetylcholinesterase cytochemistry or choline acetyl transferase immunocytochemistry are rescued efficiently by the neurotransmitter noradrenaline (NA). The effect of NA required neither adrenoceptor activation nor intracellular accumulation. NA operated via a mechanism that precluded activation of a cell death pathway in which reactive oxygen species (ROS) and proapoptotic caspases were crucially involved. It is noteworthy that NA remained protective even when applied late in the degenerative process but before intracellular ROS began to increase. The high efficacy of iron chelators and catalase in preventing the death of cholinergic neurons in this model suggested that NA neutralized the effects of hydroxyl radicals produced through a Fenton-type reaction. Pyrocatechol [the diphenolic moiety of NA] was sufficient in itself to prevent ROS production and cholinergic cell demise, indicating that the catechol structure was instrumental for the neuroprotective function of NA. Therefore, the noncatecholic neurotransmitter GABA failed to prevent neurodegeneration. Nerve growth factor and brain derived neurotrophic factor, two trophic peptides for septal cholinergic neurons, did not afford protection by themselves and did not improve neuroprotection provided by NA. However, in the presence of NA, they both retained their efficacy to stimulate cholinergic parameters. These data indicate that NA-based therapeutic strategies may be of interest in such neurodegenerative conditions as Alzheimer's disease, where progressive cholinergic deficits occur.
authors.affiliation: INSERM U679, Bātiment Pharmacie, Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital, 75013 Paris, France.
authors.forename: Sabine
authors.initials: S
authors.lastname: Traver
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Salthun-Lassalle
authors.forename: Marc
authors.initials: M
authors.lastname: Marien
authors.forename: Etienne C
authors.initials: EC
authors.lastname: Hirsch
authors.forename: Francis
authors.initials: F
authors.lastname: Colpaert
authors.forename: Patrick P
authors.initials: PP
authors.lastname: Michel
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D002795:Choline O-Acetyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D002799:Cholinergic Fibers / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D009410:Nerve Degeneration / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D009638:Norepinephrine / Q000494:pharmacology* / Q000627:therapeutic use; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D020665:Septum of Brain / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism
chemical_list: D018696:Neuroprotective Agents; D002795:Choline O-Acetyltransferase; D009638:Norepinephrine